NCT06983119 Case-Finding for Neurocognitive Disorders in Pavia
| NCT ID | NCT06983119 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS National Neurological Institute "C. Mondino" Foundation |
| Condition | Dementia |
| Study Type | INTERVENTIONAL |
| Enrollment | 490 participants |
| Start Date | 2024-07-11 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 490 participants in total. It began in 2024-07-11 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Dementia is a global public health challenge with a heavy caregiving burden, impacting families, communities, and healthcare systems. It is a priority in healthcare planning, with focus on early diagnosis and ongoing support. This research project addresses the global public health challenge posed by dementia, focusing on early detection and comprehensive care. The research evaluates the clinical, social, and healthcare impact of two dementia-related projects in Italy: 1. the first "Ricor-Dare," aims to create an integrated network for identifying new cases of dementia or Mild Cognitive Impairment (MCI) and providing care to patients and caregivers; 2. the second involves establishing a new Center for Cognitive Disorders and Dementia (CCDD) in an area previously lacking such services. The primary goal of this study is to assess the effectiveness of case-finding strategies promoted by the "Ricor-Dare" project for the early detection of cognitive decline. Researchers will compare three different settings in which case-finding will be conducted: at the general practitioners' offices, at the Dementia Operations Center, and at Open Days for the general population. The aim is to measure how many individuals in these three settings are diagnosed with Mild Cognitive Impairment (MCI) or dementia, compared to those identified as potential cases through cognitive testing. The secondary goal of the study is to assess the social, care, and prevention impact of the activities offered within the two projects. This includes evaluating the experiences of patients and families who access the new CCDD in the province of Pavia, the impact of care pathways on caregivers, and comparing the effectiveness of the new CCDD with existing ones in the region of Lombardia. The study will also assess the role of the "Ricor-Dare" project in addressing the needs of patients, caregivers, and professionals, as well as the effectiveness of awareness-raising and training activities on dementia. Overall, the study aims to provide valuable insights into improving care for people with dementia and supporting their families and caregivers.
Eligibility Criteria
For the Primary Outcome the inclusion criteria are: * Age 50 or older * Assessment conducted using GPcog/ACE-III depending on the setting * No prior diagnosis of cognitive decline * Ability to understand the study objectives and sign an informed consent For the Primary Outcome the exclusion criteria are: * Age under 50 * Presence of a diagnosis of cognitive decline * Limited knowledge of the Italian language For the secondary outcome the inclusion criteria are: Patient: * All patients/people who are included in one of the actions provided through the "Ricor-Dare" Project or who are attending a visit scheduled in the clinical-care pathway of the CDCD Fondazione Mondino Pavia or Lomellina; * Ability to understand the aims of the study and to sign an informed consent Caregiver: * Age equal to or greater than 18 years * Informal caregiver of a family member with a suspected or confirmed diagnosis of dementia who is included in one of the actions provided through the "Ricor-Dare" project or who are attending a visit scheduled in the clinical-care pathway of the CDCD; * Acceptance of informed consent and voluntary participation in the study. Healthcare professionals: * All healthcare and social healthcare professionals (GPs, pharmacists, nurses, nurses auxiliary) who practice in the cities of Pavia and Vigevano who participate in the project and agree to undergo assessments and training; * Acceptance of informed consent and voluntary participation in the study. Fo the Secondary Outcome the exclusion criteria are: Patient: \- Inability to understand the aims of the study and to sign an informed consent Caregiver: * Age under 18 * Formal caregivers, i.e. any person who provides assistance to the patient in exchange for payment of a fee; * Caregivers with limited knowledge of the Italian language.
Contact & Investigator
Alfredo Costa, MD
STUDY DIRECTOR
IRCCS National Neurological Institute "C. Mondino" Foundation
Frequently Asked Questions
Who can join the NCT06983119 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Dementia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06983119 currently recruiting?
Yes, NCT06983119 is actively recruiting participants. Contact the research team at nicola.allegri@mondino.it for enrollment information.
Where is the NCT06983119 trial being conducted?
This trial is being conducted at Pavia, Italy.
Who is sponsoring the NCT06983119 clinical trial?
NCT06983119 is sponsored by IRCCS National Neurological Institute "C. Mondino" Foundation. The principal investigator is Alfredo Costa, MD at IRCCS National Neurological Institute "C. Mondino" Foundation. The trial plans to enroll 490 participants.